Citations (165)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Tomasz Chmiela, Julia Węgrzynek, Amadeusz Kasprzyk, Damian Waksmundzki, Dawid Wilczek & Agnieszka Gorzkowska. (2022) If Not Insulin Resistance so What? – Comparison of Fasting Glycemia in Idiopathic Parkinson’s Disease and Atypical Parkinsonism. Diabetes, Metabolic Syndrome and Obesity 15, pages 1451-1460.
Read now
Read now
Xiaoyan Yang, Peng Feng, Rong Ji, Yiqing Ren, Wenshi Wei & Christian Hölscher. (2022) Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson’s disease. Expert Opinion on Therapeutic Targets 26:5, pages 445-460.
Read now
Read now
Cynthia V. Calkin. (2019) Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder. Annals of Medicine 51:5-6, pages 281-293.
Read now
Read now
Hsiu-Li Lin, Hsiu-Chen Lin, Yuan-Fu Tseng, Jane Chen-Jui Chao & Chien-Yeh Hsu. (2018) Association of thiazolidinedione with a lower risk of Parkinson’s disease in a population with newly-diagnosed diabetes mellitus. Annals of Medicine 50:5, pages 430-436.
Read now
Read now
Safia Costes, Tatyana Gurlo, Jacqueline F Rivera & Peter C Butler. (2014) UCHL1 deficiency exacerbates human islet amyloid polypeptide toxicity in β-cells. Autophagy 10:6, pages 1004-1014.
Read now
Read now
Pierre-Francois Pradat, Gaelle Bruneteau, Paul H. Gordon, Luc Dupuis, Dominique Bonnefont-Rousselot, Dominique Simon, Francois Salachas, Philippe Corcia, Vincent Frochot, Jean-Marc Lacorte, Claude Jardel, Christiane Coussieu, Nadine Le Forestier, Lucette Lacomblez, Jean-Philippe Loeffler & Vincent Meininger. (2010) Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis 11:1-2, pages 166-171.
Read now
Read now
Articles from other publishers (159)
Yuri Zilberter, Dennis R. Tabuena & Misha Zilberter. (2023) NOX-induced oxidative stress is a primary trigger of major neurodegenerative disorders. Progress in Neurobiology 231, pages 102539.
Crossref
Crossref
Fumitaka Kawakami, Motoki Imai, Yuki Isaka, Mark R. Cookson, Hiroko Maruyama, Makoto Kubo, Matthew J. Farrer, Makoto Kanzaki, Rei Kawashima, Tatsunori Maekawa, Shun Tamaki, Yoshifumi Kurosaki, Fumiaki Kojima, Kenichi Ohba & Takafumi Ichikawa. (2023)
LRRK2
negatively regulates glucose tolerance via regulation of membrane translocation of
GLUT4
in adipocytes
. FEBS Open Bio 13:12, pages 2200-2214.
Crossref
Crossref
Marco Greco, Anas Munir, Debora Musarò, Chiara Coppola & Michele Maffia. (2023) Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease. Frontiers in Neuroscience 17.
Crossref
Crossref
S. Sri Sabari, Kiruthika Balasubramani, Mahalaxmi Iyer, Harysh Winster Sureshbabu, Dhivya Venkatesan, Abilash Valsala Gopalakrishnan, Arul Narayanaswamy, Nachimuthu Senthil Kumar & Balachandar Vellingiri. (2023) Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach. Molecular Neurobiology 60:8, pages 4547-4573.
Crossref
Crossref
Priyansh Patel, Amulya Adusumilli, Dharaneswari Hari Narayanan, Diya Patel, Sunny Patel, Sai Dheeraj Gutlapalli, Sunil Patel, Kavan G Patel, Borislav Kheyson, Suzy Bibawy & Philip Otterbeck. (2023) Evaluation of Efficacy of Bromocriptine as a Therapeutic Modality in the Treatment of Diabetes Mellitus: A Systematic Review. Cureus.
Crossref
Crossref
Chengcheng Dai, Changhong Tan, Lili Zhao, Yi Liang, Guohui Liu, Hang Liu, Yuke Zhong, Zhihui Liu, Lijuan Mo, Xi Liu & Lifen Chen. (2023) Glucose metabolism impairment in Parkinson’s disease. Brain Research Bulletin 199, pages 110672.
Crossref
Crossref
A. Yu. Troshneva & A. S. Ametov. (2023) Parkinson’s Disease and Type 2 Diabetes Mellitus: Interrelated Pathogenetic Mechanisms and Common Therapeutic Approaches. Neuroscience and Behavioral Physiology 53:6, pages 959-965.
Crossref
Crossref
Mohamed Alrouji, Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Nada A. Ashour, Majid S. Jabir, Walaa A. Negm & Gaber El-Saber Batiha. (2023) Metformin role in Parkinson’s disease: a double-sword effect. Molecular and Cellular Biochemistry.
Crossref
Crossref
Ye Wang, Joakim Bergström, Martin Ingelsson & Gunilla T. Westermark. (2023) Studies on alpha-synuclein and islet amyloid polypeptide interaction. Frontiers in Molecular Biosciences 10.
Crossref
Crossref
Joseph Blommer, Toni Pitcher, Maja Mustapic, Erden Eren, Pamela J Yao, Michael P Vreones, Krishna A Pucha, John Dalrymple-Alford, Reza Shoorangiz, Wassilios G Meissner, Tim Anderson & Dimitrios Kapogiannis. (2023) Extracellular vesicle biomarkers for cognitive impairment in Parkinson’s disease. Brain 146:1, pages 195-208.
Crossref
Crossref
Zachary Freyberg & George K. Gittes. (2023) Roles of Pancreatic Islet Catecholamine Neurotransmitters in Glycemic Control and in Antipsychotic Drug–Induced Dysglycemia. Diabetes 72:1, pages 3-15.
Crossref
Crossref
Tanya S McDonald, Titaya Lerskiatiphanich, Trent M Woodruff, Pamela A McCombe & John D Lee. (2022) Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders. Journal of Cerebral Blood Flow & Metabolism 43:1, pages 26-43.
Crossref
Crossref
Pilar Vigil, Jaime Meléndez, Grace Petkovic & Juan Pablo Del Río. (2022) The importance of estradiol for body weight regulation in women. Frontiers in Endocrinology 13.
Crossref
Crossref
Manar Rashad, Mohamed Hamed & Mohamed El-Hadidi. (2022) Unravelling Diabetes-related Pathways Using 16S rRNA Microbiome Data from Human Gut and Nasal Cavity. Unravelling Diabetes-related Pathways Using 16S rRNA Microbiome Data from Human Gut and Nasal Cavity.
Débora Lanznaster, Giulia Dingeo, Rayhanatou Altine Samey, Patrick Emond & Hélène Blasco. (2022) Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases. Metabolites 12:9, pages 864.
Crossref
Crossref
Asuka A. Orr, Sarah K. Kuhlmann & Phanourios Tamamis. (2022) Computational design of a β-wrapin's N-terminal domain with canonical and non-canonical amino acid modifications mimicking curcumin's proposed inhibitory function. Biophysical Chemistry 286, pages 106805.
Crossref
Crossref
Sandeep XXXX, Mir Hilal Ahmad, Linchi Rani & Amal Chandra Mondal. (2022) Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson’s Disease: Insights into Mechanisms and Pathological Consequences. Molecular Neurobiology 59:7, pages 4466-4487.
Crossref
Crossref
Carolin Thomas, Lia Wurzer, Ernst Malle, Michael Ristow & Corina T. Madreiter-Sokolowski. (2022) Modulation of Reactive Oxygen Species Homeostasis as a Pleiotropic Effect of Commonly Used Drugs. Frontiers in Aging 3.
Crossref
Crossref
Enrique Blázquez, Verónica Hurtado-Carneiro, Yannick LeBaut-Ayuso, Esther Velázquez, Luis García-García, Francisca Gómez-Oliver, Juan Miguel Ruiz-Albusac, Jesús Ávila & Miguel Ángel Pozo. (2022) Significance of Brain Glucose Hypometabolism, Altered Insulin Signal Transduction, and Insulin Resistance in Several Neurological Diseases. Frontiers in Endocrinology 13.
Crossref
Crossref
Yifat Miller. (2022) Advancements and future directions in research of the roles of insulin in amyloid diseases. Biophysical Chemistry 281, pages 106720.
Crossref
Crossref
Ali Sarbazi-Golezari & Hashem Haghdoost-Yazdi. (2021) Chronic and progressive dopaminergic neuronal death in substantia nigra associates with a decrease in serum levels of glucose and free fatty acids, the role of interlokin-1 beta. Metabolic Brain Disease 37:2, pages 373-381.
Crossref
Crossref
Angela De Iuliis, Ennio Montinaro, Giuseppe Fatati, Mario Plebani & Carlo Colosimo. (2022) Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine. Neural Regeneration Research 17:3, pages 523.
Crossref
Crossref
A.Yu. Troshneva & A.S. Ametov. (2022) Parkinson’s disease and type 2 diabetes mellitus: interrelation of pathogenetic mechanisms and general therapeutic approaches. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 122:11, pages 12.
Crossref
Crossref
Kai-Jung Lin, Tzu-Jou Wang, Shang-Der Chen, Kai-Lieh Lin, Chia-Wei Liou, Min-Yu Lan, Yao-Chung Chuang, Jiin-Haur Chuang, Pei-Wen Wang, Jong-Jer Lee, Feng-Sheng Wang, Hung-Yu Lin & Tsu-Kung Lin. (2021) Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors. Antioxidants 10:12, pages 1935.
Crossref
Crossref
Rudy Luna, Ramya Talanki Manjunatha, Bhaswanth Bollu, Sharan Jhaveri, Chaithanya Avanthika, Nikhil Reddy, Tias Saha & Fenil Gandhi. (2021) A Comprehensive Review of Neuronal Changes in Diabetics. Cureus.
Crossref
Crossref
Marzieh Mirzae, Mohammad Hossein Abbasi, Gholam Ali Shahidi, Qodsiye Hosseinifakhr, Farzad Sina & Seyed Amirhassan Habibi. (2021) Diabetes Increases the Incidence of Levodopa-Induced Dyskinesia in Parkinson’s Disease; A Case-Control Study. Journal of Advances in Medical and Biomedical Research 29:136, pages 257-262.
Crossref
Crossref
Karina Abramov-Harpaz, Maya Pollock-Gagolashvili & Yifat Miller. (2021) Insights into the Mechanistic Perspective Effect of Insulin on the Nonamyloidogenic Component (NAC) and α-Synuclein Aggregation. ACS Chemical Neuroscience 12:17, pages 3266-3276.
Crossref
Crossref
Kambiz Hassanzadeh, Arman Rahimmi, Mohammad Raman Moloudi, Rita Maccarone, Massimo Corbo, Esmael Izadpanah & Marco Feligioni. (2021) Effect of lobeglitazone on motor function in rat model of Parkinson’s disease with diabetes co-morbidity. Brain Research Bulletin 173, pages 184-192.
Crossref
Crossref
Nadeeja Wijesekara, Rosemary Ahrens, Ling Wu, Tammy Langman, Anurag Tandon & Paul E. Fraser. (2021) α-Synuclein Regulates Peripheral Insulin Secretion and Glucose Transport. Frontiers in Aging Neuroscience 13.
Crossref
Crossref
Merve Kasap & Donard S. Dwyer. (2021) Na+ leak-current channel (NALCN) at the junction of motor and neuropsychiatric symptoms in Parkinson’s disease. Journal of Neural Transmission 128:6, pages 749-762.
Crossref
Crossref
Christine Girges, Nirosen Vijiaratnam, Dilan Athauda, Grace Auld, Sonia Gandhi & Thomas Foltynie. (2021) The Future of Incretin-Based Approaches for Neurodegenerative Diseases in Older Adults: Which to Choose? A Review of their Potential Efficacy and Suitability. Drugs & Aging 38:5, pages 355-373.
Crossref
Crossref
Shadi El-Wahsh, Elizabeth C Finger, Olivier Piguet, Vincent Mok, Jonathan D Rohrer, Matthew C Kiernan & Rebekah M Ahmed. (2021) Predictors of survival in frontotemporal lobar degeneration syndromes. Journal of Neurology, Neurosurgery & Psychiatry 92:4, pages 425-433.
Crossref
Crossref
Ruwei Ou, Qianqian Wei, Yanbing Hou, Lingyu Zhang, Kuncheng Liu, Junyu Lin, Zheng Jiang, Wei Song, Bei Cao & Huifang Shang. (2021) Effect of diabetes control status on the progression of Parkinson’s disease: A prospective study. Annals of Clinical and Translational Neurology 8:4, pages 887-897.
Crossref
Crossref
Ling-Yu Zhang, Qian-Qian Jin, Christian Hölscher & Lin Li. (2021) Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model. Neural Regeneration Research 16:8, pages 1660.
Crossref
Crossref
Feng Hong, Guang-Wen Li, Sumei Liu, Yan Zhang, Xiao-Yan Feng & Jin-Xia Zhu. 2021. Dopamine in the Gut. Dopamine in the Gut
203
232
.
Jesús D. Meléndez-Flores, Juan Manuel Millán-Alanís, Adrián González-Martínez, Neri Alejandro Álvarez-Villalobos & Ingrid Estrada-Bellmann. (2020) Does glitazone treatment have a role on the prevention of Parkinson’s disease in adult diabetic population? A systematic review. Metabolic Brain Disease 35:7, pages 1067-1075.
Crossref
Crossref
Zachary J. Farino, Travis J. Morgenstern, Antonella Maffei, Matthias Quick, Alain J. De Solis, Pattama Wiriyasermkul, Robin J. Freyberg, Despoina Aslanoglou, Denise Sorisio, Benjamin P. Inbar, R. Benjamin Free, Prashant Donthamsetti, Eugene V. Mosharov, Christoph Kellendonk, Gary J. Schwartz, David R. Sibley, Claudia Schmauss, Lori M. Zeltser, Holly Moore, Paul E. Harris, Jonathan A. Javitch & Zachary Freyberg. (2019) New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Molecular Psychiatry 25:9, pages 2070-2085.
Crossref
Crossref
Julia L.Y. Cheong, Eduardo de Pablo-Fernandez, Thomas Foltynie & Alastair J. Noyce. (2020) The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease. Journal of Parkinson's Disease 10:3, pages 775-789.
Crossref
Crossref
Samantha Molsberry, Kjetil Bjornevik, Katherine C. Hughes, Zhongli Joel Zhang, Sarah Jeanfavre, Clary Clish, Brian Healy, Michael Schwarzschild & Alberto Ascherio. (2020) Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson’s Disease. Journal of Parkinson's Disease 10:3, pages 1011-1021.
Crossref
Crossref
Simon Lam, Abdulahad Bayraktar, Cheng Zhang, Hasan Turkez, Jens Nielsen, Jan Boren, Saeed Shoaie, Mathias Uhlen & Adil Mardinoglu. (2020) A systems biology approach for studying neurodegenerative diseases. Drug Discovery Today 25:7, pages 1146-1159.
Crossref
Crossref
N.I. Verugina, O.S. Levin & E.A. Lyashenko. (2020) Neuroendocrine and metabolic impairments in patients with Parkinson’s disease. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 120:10, pages 67.
Crossref
Crossref
Alisha Chunduri, Wim E. Crusio & Anna Delprato. (2020) Narcolepsy in Parkinson's disease with insulin resistance. F1000Research 9, pages 1361.
Crossref
Crossref
Susana Cardoso & Paula I. Moreira. 2020. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases
37
64
.
Christian Hölscher. 2020. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases. Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases
65
89
.
Akhlaq A. Farooqui. 2020. Insulin Resistance as a Risk Factor in Visceral and Neurological Disorders. Insulin Resistance as a Risk Factor in Visceral and Neurological Disorders
349
384
.
Bhavani Kashyap, Leah R. Hanson & William H. Frey II. (2020) Intranasal Insulin: a Treatment Strategy for Addiction. Neurotherapeutics 17:1, pages 105-115.
Crossref
Crossref
Fauze Camargo Maluf, David Feder & Alzira Alves de Siqueira Carvalho. (2019) Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review. Parkinson's Disease 2019, pages 1-14.
Crossref
Crossref
Domenico Sergi, Justine Renaud, Nicola Simola & Maria-Grazia Martinoli. (2019) Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences. Frontiers in Aging Neuroscience 11.
Crossref
Crossref
Tara L. Kyser, Adam J. Dourson, Jennifer L. McGuire, Ann M. Hemmerle, Michael T. Williams & Kim B. Seroogy. (2019) Characterization of Motor and Non-Motor Behavioral Alterations in the Dj-1 (PARK7) Knockout Rat. Journal of Molecular Neuroscience 69:2, pages 298-311.
Crossref
Crossref
Francesca Fiory, Giuseppe Perruolo, Ilaria Cimmino, Serena Cabaro, Francesca Chiara Pignalosa, Claudia Miele, Francesco Beguinot, Pietro Formisano & Francesco Oriente. (2019) The Relevance of Insulin Action in the Dopaminergic System. Frontiers in Neuroscience 13.
Crossref
Crossref
Omid Reza Tamtaji, Mohsen Taghizadeh, Reza Daneshvar Kakhaki, Ebrahim Kouchaki, Fereshteh Bahmani, Shokoofeh Borzabadi, Shahrbanoo Oryan, Alireza Mafi & Zatollah Asemi. (2019) Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Clinical Nutrition 38:3, pages 1031-1035.
Crossref
Crossref
Neelam Sharma, Swetha Pavani Rao & Shasi V. Kalivendi. (2019) The deglycase activity of DJ-1 mitigates α-synuclein glycation and aggregation in dopaminergic cells: Role of oxidative stress mediated downregulation of DJ-1 in Parkinson's disease. Free Radical Biology and Medicine 135, pages 28-37.
Crossref
Crossref
Pavel Semenyuk, Kseniya Barinova & Vladimir Muronetz. (2019) Glycation of α-synuclein amplifies the binding with glyceraldehyde-3-phosphate dehydrogenase. International Journal of Biological Macromolecules 127, pages 278-285.
Crossref
Crossref
Kseniya Barinova, Marina Serebryakova, Evgeny Sheval, Elena Schmalhausen & Vladimir Muronetz. (2019) Modification by glyceraldehyde-3-phosphate prevents amyloid transformation of alpha-synuclein. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1867:4, pages 396-404.
Crossref
Crossref
Yoav Atsmon-Raz, Vered Wineman-Fisher, Michal Baram & Yifat Miller. (2018) Unique Inversion Events of Residues around the Backbone in the Turn Domain of β-Arches in Amylin Fibrils. ACS Chemical Neuroscience 10:3, pages 1209-1213.
Crossref
Crossref
Natalja Funk, Marita Munz, Thomas Ott, Kathrin Brockmann, Andrea Wenninger-Weinzierl, Ralf Kühn, Daniela Vogt-Weisenhorn, Florian Giesert, Wolfgang Wurst, Thomas Gasser & Saskia Biskup. (2019) The Parkinson’s disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4. Scientific Reports 9:1.
Crossref
Crossref
Robert Krikorian, Marcelle D. Shidler, Suzanne S. Summer, Patrick G. Sullivan, Andrew P. Duker, Richard S. Isaacson & Alberto J. Espay. (2019) Nutritional ketosis for mild cognitive impairment in Parkinson's disease: A controlled pilot trial. Clinical Parkinsonism & Related Disorders 1, pages 41-47.
Crossref
Crossref
Sheeza Khan & Ajaz A. Bhat. 2019. Protein Modificomics. Protein Modificomics
229
280
.
Susana Cardoso, Raquel M. Seiça & Paula I. Moreira. 2019. Mitochondria in Obesity and Type 2 Diabetes. Mitochondria in Obesity and Type 2 Diabetes
301
322
.
Ana Marques, Frédéric Dutheil, Elodie Durand, Isabelle Rieu, Aurélien Mulliez, Maria Livia Fantini, Yves Boirie & Franck Durif. (2018) Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?. Parkinsonism & Related Disorders 55, pages 122-127.
Crossref
Crossref
Sorabh Sharma & Rajeev Taliyan. (2018) High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats. Behavioural Brain Research 351, pages 17-23.
Crossref
Crossref
Asuka A. Orr, Hamed Shaykhalishahi, Ewa A. Mirecka, Sai Vamshi R. Jonnalagadda, Wolfgang Hoyer & Phanourios Tamamis. (2018) Elucidating the multi-targeted anti-amyloid activity and enhanced islet amyloid polypeptide binding of β-wrapins. Computers & Chemical Engineering 116, pages 322-332.
Crossref
Crossref
Paola de Candia & Giuseppe Matarese. (2018) Leptin and ghrelin: Sewing metabolism onto neurodegeneration. Neuropharmacology 136, pages 307-316.
Crossref
Crossref
Paula A. Q. Videira & Margarida Castro-Caldas. (2018) Linking Glycation and Glycosylation With Inflammation and Mitochondrial Dysfunction in Parkinson’s Disease. Frontiers in Neuroscience 12.
Crossref
Crossref
Gennaro PaganoSotirios PolychronisHeather WilsonBeniamino GiordanoNicola FerraraFlavia NiccoliniMarios Politis. (2018) Diabetes mellitus and Parkinson disease. Neurology 90:19.
Crossref
Crossref
José Pedro Castro, Kristina Wardelmann, Tilman Grune & André Kleinridders. (2018) Mitochondrial Chaperones in the Brain: Safeguarding Brain Health and Metabolism?. Frontiers in Endocrinology 9.
Crossref
Crossref
Steven E. Arnold, Zoe Arvanitakis, Shannon L. Macauley-Rambach, Aaron M. Koenig, Hoau-Yan Wang, Rexford S. Ahima, Suzanne Craft, Sam Gandy, Christoph Buettner, Luke E. Stoeckel, David M. Holtzman & David M. Nathan. (2018) Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums. Nature Reviews Neurology 14:3, pages 168-181.
Crossref
Crossref
Sathiya Sekar & Changiz Taghibiglou. (2018) Elevated nuclear phosphatase and tensin homolog (PTEN) and altered insulin signaling in substantia nigral region of patients with Parkinson’s disease. Neuroscience Letters 666, pages 139-143.
Crossref
Crossref
Patrik Krumpolec, Silvia Vallova, Lucia Slobodova, Veronika Tirpakova, Matej Vajda, Martin Schon, Radka Klepochova, Zuzana Janakova, Igor Straka, Stanislav Sutovsky, Peter Turcani, Jan Cvecka, Ladislav Valkovic, Chia-Liang Tsai, Martin Krssak, Peter Valkovic, Milan Sedliak, Barbara Ukropcova & Jozef Ukropec. (2017) Aerobic-Strength Exercise Improves Metabolism and Clinical State in Parkinson’s Disease Patients. Frontiers in Neurology 8.
Crossref
Crossref
Jose A. Santiago, Virginie Bottero & Judith A. Potashkin. (2017) Biological and Clinical Implications of Comorbidities in Parkinson’s Disease. Frontiers in Aging Neuroscience 9.
Crossref
Crossref
Mohsen Taghizadeh, Omid Reza Tamtaji, Ehsan Dadgostar, Reza Daneshvar Kakhaki, Fereshteh Bahmani, Javad Abolhassani, Mohammad Hossein Aarabi, Ebrahim Kouchaki, Mohammad Reza Memarzadeh & Zatollah Asemi. (2017) The effects of omega-3 fatty acids and vitamin E co-supplementation on clinical and metabolic status in patients with Parkinson's disease: A randomized, double-blind, placebo-controlled trial. Neurochemistry International 108, pages 183-189.
Crossref
Crossref
V. I. Muronetz, A. K. Melnikova, Z. N. Seferbekova, K. V. Barinova & E. V. Schmalhausen. (2017) Glycation, glycolysis, and neurodegenerative diseases: Is there any connection?. Biochemistry (Moscow) 82:8, pages 874-886.
Crossref
Crossref
Ming-Yuh Shiau, Pin-Shen Lee, Ying-Jyun Huang, Ching-Ping Yang, Chiao-Wan Hsiao, Kai-Yun Chang, Huan-Wen Chen & Yih-Hsin Chang. (2017) Role of PARL-PINK1-Parkin pathway in adipocyte differentiation. Metabolism 72, pages 1-17.
Crossref
Crossref
Eduardo De Pablo-Fernández, David P Breen, Pierre M Bouloux, Roger A Barker, Thomas Foltynie & Thomas T Warner. (2017) Neuroendocrine abnormalities in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry 88:2, pages 176-185.
Crossref
Crossref
Bridget Martinez & PhilipV Peplow. (2017) MicroRNAs in Parkinson's disease and emerging therapeutic targets. Neural Regeneration Research 12:12, pages 1945.
Crossref
Crossref
Tahmina Nasrin Poly, Md. Mohaimenul Islam, Bruno Andreas Walther, Hsuan-Chia Yang, Phung-Anh Nguyen, Chih-Wei Huang, Syed-Abdul Shabbir & Yu-Chuan (Jack) Li. (2017) Exploring the Association between Statin Use and the Risk of Parkinson’s Disease: A Meta-Analysis of Observational Studies. Neuroepidemiology 49:3-4, pages 142-151.
Crossref
Crossref
Rebekah M Ahmed, Emma M Devenney, Muireann Irish, Arne Ittner, Sharon Naismith, Lars M Ittner, Jonathan D Rohrer, Glenda M Halliday, Andrew Eisen, John R Hodges & Matthew C Kiernan. (2016) Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery & Psychiatry 87:11, pages 1234-1241.
Crossref
Crossref
Yoav Atsmon-Raz & Yifat Miller. (2016) Molecular Mechanisms of the Bindings between Non-Amyloid β Component Oligomers and Amylin Oligomers. The Journal of Physical Chemistry B 120:41, pages 10649-10659.
Crossref
Crossref
D. Athauda & T. Foltynie. (2016) Insulin resistance and Parkinson’s disease: A new target for disease modification?. Progress in Neurobiology 145-146, pages 98-120.
Crossref
Crossref
Yun Lim, Hanchae Cho & Eun-Kyoung Kim. (2016) Brain metabolism as a modulator of autophagy in neurodegeneration. Brain Research 1649, pages 158-165.
Crossref
Crossref
Claudio Procaccini, Marianna Santopaolo, Deriggio Faicchia, Alessandra Colamatteo, Luigi Formisano, Paola de Candia, Mario Galgani, Veronica De Rosa & Giuseppe Matarese. (2016) Role of metabolism in neurodegenerative disorders. Metabolism 65:9, pages 1376-1390.
Crossref
Crossref
Jacqueline A. Bayliss, Moyra B. Lemus, Vanessa V. Santos, Minh Deo, Jeffrey S. Davies, Bruce E. Kemp, John D. Elsworth & Zane B. Andrews. (2016) Metformin Prevents Nigrostriatal Dopamine Degeneration Independent of AMPK Activation in Dopamine Neurons. PLOS ONE 11:7, pages e0159381.
Crossref
Crossref
Giuseppe Perruolo, Davide Viggiano, Francesca Fiory, Angela Cassese, Cecilia Nigro, Antonietta Liotti, Claudia Miele, Francesco Beguinot & Pietro Formisano. (2016) Parkinson-like phenotype in insulin-resistant PED/PEA-15 transgenic mice. Scientific Reports 6:1.
Crossref
Crossref
Hugo Vicente Miranda, Omar M. A. El-Agnaf & Tiago Fleming Outeiro. (2016) Glycation in Parkinson's disease and Alzheimer's disease. Movement Disorders 31:6, pages 782-790.
Crossref
Crossref
Xuejing Yue, Hehua Li, Haiqing Yan, Ping Zhang, Li Chang & Tong Li. (2016) Risk of Parkinson Disease in Diabetes Mellitus. Medicine 95:18, pages e3549.
Crossref
Crossref
Estifanos Baye, Barbara Ukropcova, Jozef Ukropec, Alan Hipkiss, Giancarlo Aldini & Barbora de Courten. (2016) Physiological and therapeutic effects of carnosine on cardiometabolic risk and disease. Amino Acids 48:5, pages 1131-1149.
Crossref
Crossref
Juhyun Song & Jongpil Kim. (2016) Degeneration of Dopaminergic Neurons Due to Metabolic Alterations and Parkinson’s Disease. Frontiers in Aging Neuroscience 8.
Crossref
Crossref
Rebekah M Ahmed, Muireann Irish, Olivier Piguet, Glenda M Halliday, Lars M Ittner, Sadaf Farooqi, John R Hodges & Matthew C Kiernan. (2016) Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. The Lancet Neurology 15:3, pages 332-342.
Crossref
Crossref
Sun Ju Chung, Mi-Jung Kim, Juyeon Kim, Ho-Sung Ryu, Young Jin Kim, Seong Yoon Kim & Jae-Hong Lee. (2015) Association of type 2 diabetes GWAS loci and the risk of Parkinson's and Alzheimer's diseases. Parkinsonism & Related Disorders 21:12, pages 1435-1440.
Crossref
Crossref
Jose A. Santiago & Judith A. Potashkin. (2015) Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson’s Disease Patients. PLOS ONE 10:11, pages e0142582.
Crossref
Crossref
Javier Ruiz-Martinez, Catharine E Krebs, Vladimir Makarov, Ana Gorostidi, Jose Félix Martí-Massó & Coro Paisán-Ruiz. (2015) GIGYF2 mutation in late-onset Parkinson’s disease with cognitive impairment. Journal of Human Genetics 60:10, pages 637-640.
Crossref
Crossref
JULIAN BANERJI. (2015) Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis). International Journal of Molecular Medicine 36:3, pages 607-626.
Crossref
Crossref
Brett A. Kaufman, Changhong Li & Scott A. Soleimanpour. (2015) Mitochondrial regulation of β-cell function: Maintaining the momentum for insulin release. Molecular Aspects of Medicine 42, pages 91-104.
Crossref
Crossref
Andre Kleinridders, Weikang Cai, Laura Cappellucci, Armen Ghazarian, William R. Collins, Sara G. Vienberg, Emmanuel N. Pothos & C. Ronald Kahn. (2015) Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proceedings of the National Academy of Sciences 112:11, pages 3463-3468.
Crossref
Crossref
Trine Gjerløff, Tatyana Fedorova, Karoline Knudsen, Ole L. Munk, Adjmal Nahimi, Steen Jacobsen, Erik H. Danielsen, Astrid J. Terkelsen, John Hansen, Nicola Pavese, David J. Brooks & Per Borghammer. (2015) Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain 138:3, pages 653-663.
Crossref
Crossref
Joanne L. Hopper, Natasha Begum, Laura Smith & Thomas A. Hughes. (2015) The role of PSMD9 in human disease: future clinical and therapeutic implications. AIMS Molecular Science 2:4, pages 476-484.
Crossref
Crossref
Gregory Oxenkrug. 2015. Tryptophan Metabolism: Implications for Biological Processes, Health and Disease. Tryptophan Metabolism: Implications for Biological Processes, Health and Disease
173
195
.
Gianfranco Politano, Alfredo Benso, Alessandro Savino & Stefano Di Carlo. (2014) ReNE: A Cytoscape Plugin for Regulatory Network Enhancement. PLoS ONE 9:12, pages e115585.
Crossref
Crossref
I.I. Stoyanova. (2014) Ghrelin: A link between ageing, metabolism and neurodegenerative disorders. Neurobiology of Disease 72, pages 72-83.
Crossref
Crossref
Rebekah M. AhmedMia MacMillanLauren BartleyGlenda M. HallidayMatthew C. KiernanJohn R. HodgesOlivier Piguet. (2014) Systemic metabolism in frontotemporal dementia. Neurology 83:20, pages 1812-1818.
Crossref
Crossref
Ye Chen, Feng Hong, Hui Chen, Rui-Fang Fan, Xiao-Li Zhang, Yue Zhang & Jin-Xia Zhu. (2014) Distinctive expression and cellular distribution of dopamine receptors in the pancreatic islets of rats. Cell and Tissue Research 357:3, pages 597-606.
Crossref
Crossref
André Kleinridders, Heather A. Ferris, Weikang Cai & C. Ronald Kahn. (2014) Insulin Action in Brain Regulates Systemic Metabolism and Brain Function. Diabetes 63:7, pages 2232-2243.
Crossref
Crossref
Fares Bassil, Pierre-Olivier Fernagut, Erwan Bezard & Wassilios G. Meissner. (2014) Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?. Progress in Neurobiology 118, pages 1-18.
Crossref
Crossref
Andrea Kistner, Eugénie Lhommée & Paul Krack. (2014) Mechanisms of Body Weight Fluctuations in Parkinson’s Disease. Frontiers in Neurology 5.
Crossref
Crossref
Emma Deas, Kaisa Piipari, Asif Machhada, Abi Li, Ana Gutierrez-del-Arroyo, Dominic J. Withers, Nicholas W. Wood & Andrey Y. Abramov. (2014) PINK1 deficiency in β-cells increases basal insulin secretion and improves glucose tolerance in mice. Open Biology 4:5, pages 140051.
Crossref
Crossref
Sarah M. Rothman, Kathleen J. Griffioen, Kenneth W. Fishbein, Richard G. Spencer, Sokratis Makrogiannis, Wei-na Cong, Bronwen Martin & Mark P. Mattson. (2014) Metabolic abnormalities and hypoleptinemia in α-synuclein A53T mutant mice. Neurobiology of Aging 35:5, pages 1153-1161.
Crossref
Crossref
Hutan Ashrafian, Leanne Harling, Ara Darzi & Thanos Athanasiou. (2013) Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions?. Metabolic Brain Disease 28:3, pages 341-353.
Crossref
Crossref
Alessandro Ustione, David W. Piston & Paul E. Harris. (2013) Minireview: Dopaminergic Regulation of Insulin Secretion from the Pancreatic Islet. Molecular Endocrinology 27:8, pages 1198-1207.
Crossref
Crossref
Luciana Mendonça Arantes, Natalia Oliveira Bertolini, Rodrigo Ferreira de Moura, Maria Alice Rostom de Mello & Eliete Luciano. (2013) Insulin concentrations in cerebellum and body balance in diabetic male rats: Aerobic training effects. Physiology & Behavior 118, pages 58-62.
Crossref
Crossref
Rasoul Ghasemi, Leila Dargahi, Ali Haeri, Maryam Moosavi, Zahurin Mohamed & Abolhassan Ahmadiani. (2013) Brain Insulin Dysregulation: Implication for Neurological and Neuropsychiatric Disorders. Molecular Neurobiology 47:3, pages 1045-1065.
Crossref
Crossref
Vikas Kotagal, Roger L. Albin, Martijn L.T.M. Müller, Robert A. Koeppe, Kirk A. Frey & Nicolaas I. Bohnen. (2013) Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism & Related Disorders 19:5, pages 522-526.
Crossref
Crossref
Iciar Aviles-Olmos, Patricia Limousin, Andrew Lees & Thomas Foltynie. (2013) Parkinson's disease, insulin resistance and novel agents of neuroprotection. Brain 136:2, pages 374-384.
Crossref
Crossref
G.O. Skeie, B. Muller, K. Haugarvoll, J.P. Larsen & O.B. Tysnes. (2013) Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism & Related Disorders 19:1, pages 53-55.
Crossref
Crossref
Peter Riederer, Jasmin Bartl, Gerd Laux & Edna Gruünblatt. 2013. Staging Neuropsychiatric Disorders. Staging Neuropsychiatric Disorders
171
183
.
Alessandro Ustione & David W. Piston. (2012) Dopamine Synthesis and D3 Receptor Activation in Pancreatic β-Cells Regulates Insulin Secretion and Intracellular [Ca2+] Oscillations. Molecular Endocrinology 26:11, pages 1928-1940.
Crossref
Crossref
Mark L. Wahlqvist, Meei-Shyuan Lee, Chih-Cheng Hsu, Shao-Yuan Chuang, Jiunn-Tay Lee & Hsin-Ni Tsai. (2012) Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism & Related Disorders 18:6, pages 753-758.
Crossref
Crossref
Ming Lu & Gang Hu. (2012) Targeting metabolic inflammation in Parkinson’s disease: Implications for prospective therapeutic strategies. Clinical and Experimental Pharmacology and Physiology 39:6, pages 577-585.
Crossref
Crossref
Khanh vinh quô′c Lương & Lan Thi Hoàng Nguyê∼n. (2012) Thiamine and Parkinson's disease. Journal of the Neurological Sciences 316:1-2, pages 1-8.
Crossref
Crossref
Ying Piao, Hyo Geun Kim, Myung Sook Oh & Youngmi Kim Pak. (2012) Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP+-induced mitochondrial dysfunctions in neuronal cells. Biochimica et Biophysica Acta (BBA) - General Subjects 1820:5, pages 577-585.
Crossref
Crossref
Peter Riederer, Jasmin Bartl, Gerd Laux & Edna Gruünblatt. 2012. Staging Neuropsychiatric Disorders. Staging Neuropsychiatric Disorders
153
165
.
Joanne Clark, Sonika Reddy, Kangni Zheng, Rebecca A Betensky & David K Simon. (2011) Association of PGC-1alphapolymorphisms with age of onset and risk of Parkinson's disease. BMC Medical Genetics 12:1.
Crossref
Crossref
J.K. Morris, N.B. Seim, G.L. Bomhoff, P.C. Geiger & J.A. Stanford. (2011) Effects of unilateral nigrostriatal dopamine depletion on peripheral glucose tolerance and insulin signaling in middle aged rats. Neuroscience Letters 504:3, pages 219-222.
Crossref
Crossref
Isabelle Rieu, Bruno Pereira, Philippe Derost, Miguel Ulla, Ana Marques, Jean-Jacques Lemaire, Yves Boirie & Franck Durif. (2011) Does deep brain stimulation of the subthalamic nucleus induce metabolic syndrome in Parkinson’s disease?. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 6:3, pages e126-e130.
Crossref
Crossref
Eva Schernhammer, Johnni Hansen, Kathrine Rugbjerg, Lene Wermuth & Beate Ritz. (2011) Diabetes and the Risk of Developing Parkinson’s Disease in Denmark. Diabetes Care 34:5, pages 1102-1108.
Crossref
Crossref
Qun Xu, Yikyung Park, Xuemei Huang, Albert Hollenbeck, Aaron Blair, Arthur Schatzkin & Honglei Chen. (2011) Diabetes and Risk of Parkinson’s Disease. Diabetes Care 34:4, pages 910-915.
Crossref
Crossref
Xuehui GengHaiyan Lou, Jian Wang, Lehong LiAlexandra L. Swanson, Ming SunDonna Beers-StolzSimon WatkinsRuth G. Perez & Peter Drain. (2011)
α-Synuclein binds the K
ATP
channel at insulin-secretory granules and inhibits insulin secretion
. American Journal of Physiology-Endocrinology and Metabolism 300:2, pages E276-E286.
Crossref
Crossref
Peter Riederer, Jasmin Bartl, Gerd Laux & Edna Grünblatt. (2010) Diabetes Type II: A Risk Factor for Depression–Parkinson–Alzheimer?. Neurotoxicity Research 19:2, pages 253-265.
Crossref
Crossref
Przemyslaw (Mike) Sapieha & Lois Smith. 2011. Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis. Hormones in Neurodegeneration, Neuroprotection, and Neurogenesis
171
187
.
I. Rieu, Y. Boirie, B. Morio, P. Derost, M. Ulla, A. Marques, B. Debilly, S. Bannier & F. Durif. (2010) La maladie de Parkinson idiopathique : une maladie métabolique ?. Revue Neurologique 166:10, pages 822-828.
Crossref
Crossref
M. Moreira-Rodrigues, J. Quelhas-Santos, P. Serrao, C. Fernandes-Cerqueira, B. Sampaio-Maia & M. Pestana. (2010) Glycaemic control with insulin prevents the reduced renal dopamine D1 receptor expression and function in streptozotocin-induced diabetes. Nephrology Dialysis Transplantation 25:9, pages 2945-2953.
Crossref
Crossref
N. Ahuja, N. Palanichamy, P. Mackin & AJ Lloyd. (2008) Olanzapine-induced hyperglycaemic coma and neuroleptic malignant syndrome: case report and review of literature. Journal of Psychopharmacology 24:1, pages 125-130.
Crossref
Crossref
Susana Cardoso, Renato Santos, Sonia Correia, Cristina Carvalho, Xiongwei Zhu, Hyoung-Gon Lee, Gemma Casadesus, Mark Smith, George Perry & Paula Moreira. (2009) Insulin and Insulin-Sensitizing Drugs in Neurodegeneration: Mitochondria as Therapeutic Targets. Pharmaceuticals 2:3, pages 250-286.
Crossref
Crossref
Marco D'Amelio, Paolo Ragonese, Graziella Callari, Norma Di Benedetto, Barbara Palmeri, Valeria Terruso, Giuseppe Salemi, Giorgia Famoso, Paolo Aridon & Giovanni Savettieri. (2009) Diabetes preceding Parkinson's disease onset. A case–control study. Parkinsonism & Related Disorders 15:9, pages 660-664.
Crossref
Crossref
Michela Barichella, Emanuele Cereda & Gianni Pezzoli. (2009) Major nutritional issues in the management of Parkinson's disease. Movement Disorders 24:13, pages 1881-1892.
Crossref
Crossref
Hyeo-Il Ma, Jin-Hyuck Kim, Min-Kyung Chu, Mi-Sun Oh, Kyung-Ho Yu, Jooyong Kim, Woong Hahm, Yun Joong Kim & Byung-Chul Lee. (2009) Diabetes mellitus and drug-induced parkinsonism: A case–control study. Journal of the Neurological Sciences 284:1-2, pages 140-143.
Crossref
Crossref
Yazhou LiTracyAnn PerryMark S. KindyBrandon K. HarveyDavid TweedieHarold W. HollowayKathleen PowersHui ShenJosephine M. EganKumar SambamurtiArnold BrossiDebomoy K. Lahiri, Mark P. MattsonBarry J. Hoffer, Yun WangNigel H. Greig. (2009) GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proceedings of the National Academy of Sciences 106:4, pages 1285-1290.
Crossref
Crossref
Giuseppe Giovanni. 2009. Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra. Birth, Life and Death of Dopaminergic Neurons in the Substantia Nigra
317
331
.
J.K. Morris, H. Zhang, A.A. Gupte, G.L. Bomhoff, J.A. Stanford & P.C. Geiger. (2008) Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Research 1240, pages 185-195.
Crossref
Crossref
Jane A. Driver, Ashley Smith, Julie E. Buring, J. Michael Gaziano, Tobias Kurth & Giancarlo Logroscino. (2008) Prospective Cohort Study of Type 2 Diabetes and the Risk of Parkinson's Disease. Diabetes Care 31:10, pages 2003-2005.
Crossref
Crossref
Frauke Adams, Michael Boschmann, Elmar Lobsien, Andreas Kupsch, Axel Lipp, Gabriele Franke, Marie Charlotte Leisse, Juergen Janke, Simone Gottschalk, Joachim Spranger & Jens Jordan. (2008) Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson’s disease. European Journal of Clinical Pharmacology 64:9, pages 863-870.
Crossref
Crossref
Linda B. Moran & Manuel B. Graeber. (2008) Towards a pathway definition of Parkinson’s disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 9:1, pages 1-13.
Crossref
Crossref
Georges Brousse, Alexandre Meary, Jacques Mouret, Olivier Blanc, Thierry Hueber, Philippe Lemoine, Pierre-Michel Llorca & Bernard Lachaux. (2007) Tardive dyskinesia and glucid metabolism. Human Psychopharmacology: Clinical and Experimental 22:6, pages 373-380.
Crossref
Crossref
Gang Hu, Pekka Jousilahti, Siamak Bidel, Riitta Antikainen & Jaakko Tuomilehto. (2007) Type 2 Diabetes and the Risk of Parkinson's Disease. Diabetes Care 30:4, pages 842-847.
Crossref
Crossref
K. R. Wilhelm, K. Yanamandra, M. A. Gruden, V. Zamotin, M. Malisauskas, V. Casaite, A. Darinskas, L. Forsgren & L. A. Morozova-Roche. (2007) Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. European Journal of Neurology 0:0, pages 070206022829002-???.
Crossref
Crossref
Kenichi Kashihara. (2006) Weight loss in Parkinson’s disease. Journal of Neurology 253:S7, pages vii38-vii41.
Crossref
Crossref
Blanca Rubí, Sanda Ljubicic, Shirin Pournourmohammadi, Stefania Carobbio, Mathieu Armanet, Clarissa Bartley & Pierre Maechler. (2005) Dopamine D2-like Receptors Are Expressed in Pancreatic Beta Cells and Mediate Inhibition of Insulin Secretion. Journal of Biological Chemistry 280:44, pages 36824-36832.
Crossref
Crossref
Caroline Perlemoine, Frédéric Macia, François Tison, Isabelle Coman, Dominique Guehl, Pierre Burbaud, Emmanuel Cuny, Laurence Baillet, Henri Gin & Vincent Rigalleau. (2007) Effects of subthalamic nucleus deep brain stimulation and levodopa on energy production rate and substrate oxidation in Parkinson's disease. British Journal of Nutrition 93:2, pages 191-198.
Crossref
Crossref
Aditi Marwaha, Anees Ahmad Banday & Mustafa F. Lokhandwala. (2004)
Reduced renal dopamine D
1
receptor function in streptozotocin-induced diabetic rats
. American Journal of Physiology-Renal Physiology 286:3, pages F451-F457.
Crossref
Crossref
Sandrine Thuret, Lavinia Bhatt, Dennis D.M O'Leary & Horst H Simon. (2004) Identification and developmental analysis of genes expressed by dopaminergic neurons of the substantia nigra pars compacta. Molecular and Cellular Neuroscience 25:3, pages 394-405.
Crossref
Crossref
Suzanne Craft & G Stennis Watson. (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. The Lancet Neurology 3:3, pages 169-178.
Crossref
Crossref
Hiroki Yokoo, Tomokazu Saitoh, Seiji Shiraishi, Toshihiko Yanagita, Takashi Sugano, Shin-Ichi Minami, Hideyuki Kobayashi & Akihiko Wada. (2003) Distinct Effects of Ketone Bodies on Down-Regulation of Cell Surface Insulin Receptor and Insulin Receptor Substrate-1 Phosphorylation in Adrenal Chromaffin Cells. Journal of Pharmacology and Experimental Therapeutics 304:3, pages 994-1002.
Crossref
Crossref
E Mazzio & K.F.A Soliman. (2003) d-(+)-Glucose rescue against 1-methyl-4-phenylpyridinium toxicity through anaerobic glycolysis in neuroblastoma cells. Brain Research 962:1-2, pages 48-60.
Crossref
Crossref
J.C. PressleyE.D. LouisM.-X. TangL. CoteP.D. CohenS. GliedR. Mayeux. (2003) The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 60:1, pages 87-93.
Crossref
Crossref
Elizabeth Mazzio & Karam F.A. Soliman. (2003) The Role of Glycolysis and Gluconeogenesis in the Cytoprotection of Neuroblastoma Cells against 1-Methyl 4-Phenylpyridinium Ion Toxicity. NeuroToxicology 24:1, pages 137-147.
Crossref
Crossref
C.R Park. (2001) Cognitive effects of insulin in the central nervous system. Neuroscience & Biobehavioral Reviews 25:4, pages 311-323.
Crossref
Crossref
Seiji Shiraishi, Ryuichi Yamamoto, Toshihiko Yanagita, Hiroki Yokoo, Hideyuki Kobayashi, Yasuhito Uezono & Akihiko Wada. (2001) Down-regulation of cell surface insulin receptors by sarco(endo)plasmic reticulum Ca2+-ATPase inhibitor in adrenal chromaffin cells. Brain Research 898:1, pages 152-157.
Crossref
Crossref
MARK P. MATTSON, WARD A. PEDERSEN, WENZHEN DUAN, CARSTEN CULMSEE & SIMONETTA CAMANDOLA. (1999) Cellular and Molecular Mechanisms Underlying Perturbed Energy Metabolism and Neuronal Degeneration in Alzheimer's and Parkinson's Diseases. Annals of the New York Academy of Sciences 893:1 OXIDATIVE/ENE, pages 154-175.
Crossref
Crossref
Yadollah Harati. (1996) DIABETES AND THE NERVOUS SYSTEM. Endocrinology and Metabolism Clinics of North America 25:2, pages 325-359.
Crossref
Crossref
M. Ishida, K. Otani, S. Kaneko, H. Ishida & S. Kawashima. (1996) Hyperglycemia as a symptom of neuroleptic malignant syndrome. Human Psychopharmacology: Clinical and Experimental 11:2, pages 137-138.
Crossref
Crossref